> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Drug Approval Trends Slipping: Financial Analysts
- URL: https://www.fdaweb.com/fda-drug-approval-trends-slipping-financial-analysts/
- Published: 2025-10-20T12:00:00.000Z
- Updated: 2026-09-14T15:24:27.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160070

A new report by RBC Capital Markets analyzing FDA approval trends finds a slowdown in drug approvals, a rise in rejected applications, and an increase in delayed reviews during the third quarter. Financial analysts found that the drug approval rate dropped to 73% in the third quarter, a significant decrease from the previous average of 87%. The analysis also highlighted a rise in rejected marketing applications to 15% and a 11% rate of delayed reviews, both higher than their historical averages. RBC attributes these trends to potential dysfunction at FDA, possibly compounded by short-staffing and leadership turnover.